NASDAQ: RAPPRapport Therapeutics Inc Stock
$38.40+3.19 (+9.06%)
Updated Jun 12, 2026
RAPP Price
$38.40
Fair Value Price
$0.88
Market Cap
$1.84B
52 Week Low
$10.51
52 Week High
$42.27
P/E
-14.83x
P/B
3.9x
P/S
73.9x
PEG
N/A
Dividend Yield
N/A
Revenue
$20.00M
Earnings
-$107.28M
Gross Margin
100%
Operating Margin
-536.39%
Profit Margin
-536.4%
Debt to Equity
0.06
Operating Cash Flow
-$80M
Beta
1.38
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
RAPP Overview
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RAPP's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
RAPP
Ranked#86 of 463
Ranked#86 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.56 | A | |
| $53.13 | A | |
| $15.82 | A |
Be the first to know about important RAPP news, forecast changes, insider trades & much more!
RAPP News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RAPP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RAPP ($38.40) is overvalued by 4,282.7% relative to our estimate of its Fair Value price of $0.88 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
RAPP ($38.40) is not significantly undervalued (4,282.7%) relative to our estimate of its Fair Value price of $0.88 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RAPP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RAPP due diligence checks available for Premium users.
Valuation
RAPP fair value
Fair Value of RAPP stock based on Discounted Cash Flow (DCF)
Price
$38.40
Fair Value
$0.88
Overvalued by
4,282.70%
RAPP ($38.40) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RAPP ($38.40) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RAPP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RAPP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-14.83x
Industry
16.53x
Market
14.15x
RAPP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.9x
Industry
4.85x
RAPP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RAPP's financial health
Profit margin
Revenue
$20.0M
Net Income
-$19.9M
Profit Margin
-99.3%
RAPP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
RAPP's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$497.6M
Liabilities
$26.1M
Debt to equity
0.06
RAPP's short-term assets ($484.70M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RAPP's short-term assets ($484.70M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RAPP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$13.1M
Investing
$37.9M
Financing
$531.0k
RAPP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RAPP vs Biotech Stocks
Rapport Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.